Nov 11, 2022
The Liver Meeting 2022
The Liver Meeting 2022, the largest and most prestigious international conference on the liver is taking place in the Water E Washington Convention Center from Nov 4-8.
On November 6th, HBVtech gave an oral presentation titled” Shortening HBV treatment and preventing HBV relapse by adding an anti-HBs expressing AAV- vector to entecavir therapy in HBV infected uPA/SCID chimeric mice” in the TLM22.
HBVtech delivered three important findings in the effort to effectively cure chronic hepatitis B infection.
1. HBV infection rebound after current antiviral therapy stops is mainly caused by expanded new rounds of infection and can be effectively prevented with added HBVZ10, a leading HBV cure drug developed by HBVtech.
2. HBVtech’s new hepatitis B cure strategy accelerates serological transition and shortens HBV curative course that usually takes years with current therapies, to a few months.
3. A complete anti-HBs seroconversion is a turning point in HBV curative treatment, leading to more effective HBV functional cure.